Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.99 is in line with its 5-year average of -2.04, around the middle of its 5-year range (-3.56–-0.84).
10.86% below its 12-month average of -1.79.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.30.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.99
EARNINGS PER SHARE (EPS) AVG TTM
-1.79
EARNINGS PER SHARE (EPS) AVG 3Y
-1.44
EARNINGS PER SHARE (EPS) AVG 5Y
-2.04
EARNINGS PER SHARE (EPS) AVG 10Y
-10.83
EARNINGS PER SHARE (EPS) AVG 15Y
-10.22
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-10.86%
CURRENT VS 3Y AVG
-38.19%
CURRENT VS 5Y AVG
+2.53%
CURRENT VS 10Y AVG
+81.63%
CURRENT VS 15Y AVG
+80.53%
CURRENT VS 20Y AVG
N/A
Larimar Therapeutics, Inc.
Market Cap
$285.16M
Earnings Per Share (EPS)
-1.99
TTM Avg
-1.79
3Y Avg
-1.44
5Y Avg
-2.04
Market Cap
$286.94M
Earnings Per Share (EPS)
N/A
TTM Avg
-2880.36
3Y Avg
-1920.24
5Y Avg
-1440.18
Market Cap
$281.16M
Earnings Per Share (EPS)
-1.21
TTM Avg
-0.67
3Y Avg
-1.32
5Y Avg
-1.70
Market Cap
$279.56M
Earnings Per Share (EPS)
-1.11
TTM Avg
-0.10
3Y Avg
-2.07
5Y Avg
-8.75
Market Cap
$292.07M
Earnings Per Share (EPS)
-0.23
TTM Avg
-0.20
3Y Avg
-1.19
5Y Avg
-1.02
Market Cap
$275.95M
Earnings Per Share (EPS)
-1.39
TTM Avg
-0.76
3Y Avg
-0.82
5Y Avg
-19.50
Market Cap
$272.91M
Earnings Per Share (EPS)
-6.97
TTM Avg
-33.27
3Y Avg
-41.62
5Y Avg
-70.95
Market Cap
$272.17M
Earnings Per Share (EPS)
-1.05
TTM Avg
-1.40
3Y Avg
-1.83
5Y Avg
-1.95
Market Cap
$304.56M
Earnings Per Share (EPS)
-0.98
TTM Avg
-1.02
3Y Avg
-4.71
5Y Avg
-10.90
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Larimar Therapeutics, Inc. (LRMR) | $285.16M | -1.99 | -1.79 | -1.44 | -2.04 |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $286.94M | N/A | -2880.36 | -1920.24 | -1440.18 |
| Fulcrum Therapeutics, Inc. (FULC)vs › | $281.16M | -1.21 | -0.67 | -1.32 | -1.70 |
| Abeona Therapeutics Inc. (ABEO)vs › | $279.56M | -1.11 | -0.10 | -2.07 | -8.75 |
| Standard BioTools Inc. (LAB)vs › | $292.07M | -0.23 | -0.20 | -1.19 | -1.02 |
| Aurora Cannabis Inc. (ACB)vs › | $275.95M | -1.39 | -0.76 | -0.82 | -19.50 |
| Indaptus Therapeutics, Inc. (INDP)vs › | $272.91M | -6.97 | -33.27 | -41.62 | -70.95 |
| Fate Therapeutics, Inc. (FATE)vs › | $272.17M | -1.05 | -1.40 | -1.83 | -1.95 |
| Benitec Biopharma Inc. (BNTC)vs › | $304.56M | -0.98 | -1.02 | -4.71 | -10.90 |
| Mobia Medical, Inc. Common Stock (MOBI)vs › | $306.66M | N/A | -0.02 | -0.02 | -0.02 |
Trailing EPS (TTM)
$-1.99
Forward EPS (Est.)
$-1.39
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.27 |
| 2024-12-31 | -1.32 |
| 2023-12-31 | -0.84 |
| 2022-12-31 | -1.33 |
| 2021-12-31 | -2.93 |
| 2020-12-31 | -3.56 |
| 2019-12-31 | -2.51 |
| 2018-12-31 | -22.85 |
| 2017-12-31 | -22.76 |
| 2016-12-31 | -25.44 |
| 2015-12-31 | -33.32 |
| 2014-12-31 | -15.14 |
| 2013-12-31 | -6.54 |
| 2012-12-31 | -6.40 |
| 2011-12-31 | -6.07 |
